Brexucabtagene Autoleucel (Tecartus)

Abstract


 CADTH recommends that Tecartus should be reimbursed by public drug plans for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL) after 2 or more lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor if certain conditions are met.
 Tecartus should only be reimbursed if prescribed as a one-time therapy by experienced specialists in centres delivering cellular therapies, and the cost of Tecartus is reduced.
 Tecartus should only be covered to treat patients with R/R MCL who have received treatment with a BTK inhibitor (ibrutinib or acalabrutinib) and are in a clinically reasonable health status to tolerate the treatment.